Ir al contenido principal
Close up of scientist's hand with hemp leaves at indoor cannabis farm, medical and biology concept.

Living with chronic pain: could treatment at a medical cannabis clinic be an alternative option?

If you live with chronic pain, you’ll likely already know just how debilitating it can be. Whether it’s a form of arthritis, sciatica, or lower back pain, the type of chronic pain you live with can lead to far more than just a painful sensation itself.

Chronic pain can also dictate how well you manage to sleep, work and, ultimately, how much you’re able to enjoy your day-to-day life.

Patrocinado

Releaf

Releaf es un CQC-regulated medical cannabis clinic, with a 4.8 rating on Trustpilot from over 11,000 verified reviews. Back in July 2026, it became the world's first medical cannabis clinic to earn B Corp Certification.

Managing chronic pain

For many people, conventional painkillers help to make life more bearable and symptoms easier to manage. But they’re not perfect, and their side effects are well documented. Some can even lead to dependence1 with long-term use.

This can leave chronic pain patients in a bit of a predicament, with many often searching for alternative solutions to make their symptoms more manageable.

Thanks to sweeping reforms in UK law in November 2018,2 medical cannabis consultations and treatments are now legally available from CQC-regulated providers, such as Releaf, and may be prescribed to eligible patients to take alongside their existing treatment. But what does the evidence say about its use, and who can be prescribed it?

Here, we take a closer look at what chronic pain involves, what the latest research tells us, and how to find out whether medical cannabis could be an option for you.

The stats behind the UK’s chronic pain epidemic

Chronic pain is a bit of a hidden epidemic in the UK these days.

Around 28 million adults in the UK3 are estimated to currently live with some form of chronic pain, which is equivalent to approximately 43% of the entire adult population.

Lower back pain is particularly common, with up to 60% of adults4 said to be affected at some point in their lives.

The conventional treatments used to combat chronic pain-related conditions5 typically include non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, nerve pain agents, or opioid-based painkillers.

While these can be effective short-term solutions, long-term use has been shown to lead to issues ranging from gastrointestinal problems6 to dependence, abuse, and addiction.1

Meanwhile, medical cannabis prescriptions have more than doubled between 2023 and 2024, rising from around 283,000 to 659,000.

What options are there when conventional treatments haven’t eased chronic pain symptoms?

If you’ve not been able to control your chronic pain with conventional treatments, it’s worth speaking to your doctor. Depending on the type of pain you have, the conventional options offered to you may include:5

  • A review of your medication.

  • Fisioterapia.

  • A supervised exercise programme.

  • Psychological therapies such as cognitive behavioural therapy (CBT).

  • A pain management programme.

  • Referral to a specialist pain clinic.

For certain people whose pain hasn’t responded to at least two conventional treatments, a specialist may also suggest assessing your eligibility for a medical cannabis prescription.

"Chronic pain is a lifelong condition that can be debilitating and significantly contribute to poor quality of life.

The biopsychosocial model of managing chronic pain involves treating the whole person, managing their pain, and supporting them socially and psychologically.

Some patients choose Releaf to help manage some of the symptoms that often co-exist in chronic pain conditions, such as anxiety, sleep-related disturbances, and depression."

Dr Farrah Ayob
Pain Specialist

How does medical cannabis work?

For eligible patients, having a medical cannabis prescription may help to manage certain symptoms associated with chronic pain.

While it can’t treat the underlying cause of conditions such as arthritis or lower back pain, it may help to alleviate several secondary symptoms that come with these diagnoses, such as sleep-related issues, ansiedad, y pain perception.

This is largely due to the two main active ingredients that medical cannabis contains: tetrahydrocannabinol (THC) and cannabidiol (CBD).

These compounds interact with the body’s endocannabinoid system (ECS), a complex cell-signalling network involved in important physiological and cognitive processes,7 such as our ability to regulate pain, inflammation, sleep, appetite, and mood.

Cannabinoids and the endocannabinoid system

The ECS is a complex network characterised by two main receptors, CB1 and CB2.

  • CB1 receptors are mainly found in the brain and nervous system and are generally involved in pain signalling.

  • CB2 receptors are found largely on immune cells and within joint tissues, where they help to regulate inflammation.

Cannabinoids such as THC and CBD interact with these receptors in different ways, causing various effects on the body.

  • THC acts on CB1 receptors in the nervous system, where it’s believed to help reduce pain perception and promote sleep and relaxation.8 It also has psychoactive properties, which is why it’s often associated with the ‘high’ sensation many relate to cannabis.

  • CBD is non-intoxicating7 and - rather than binding strongly to either receptor - is thought to influence the ECS indirectly. It may also help to slow the breakdown of endocannabinoids,9 which may support the body’s natural regulation of processes like pain perception and inflammation.

Depending on the unique combination of cannabinoids contained within the medical cannabis you’re prescribed, this may lead to different therapeutic effects, which is why having a clinician-led approach is crucial.

Because every patient can respond to cannabinoids differently, only a trained specialist will be able to identify the right balance of cannabinoids for your specific needs.

What does the research say?

For a long time, research into medical cannabis and chronic pain has been fairly limited, with larger, higher-quality trials still needed to confirm the relationship between the two. But recent studies are starting to change that, allowing us to understand how medical cannabis may help to alleviate symptoms in certain related conditions.

Chronic lower back pain

Back in 2025, a large phase 3 clinical trial published in Nature Medicine became one of the first high-quality studies to directly assess the impact of cannabis on chronic lower back pain.10

During the trial, 820 adult patients were given either a placebo (426 patients) or a full-spectrum cannabis extract called VER-01 (394 patients) and then analysed over an initial 12-week study period.

Over the first 12 weeks, patients in the cannabis group reported a notable decrease in pain symptoms compared to the placebo.

That improvement continued in the following months, with VER-01 patients reporting significant benefits in terms of sleep and physical function.

However, it’s worth noting that VER-01 is a specific, standardised extract, so these results may not apply to all cannabis-based medicines.

Artritis

Research into medical cannabis for arthritis is at an earlier stage than chronic back pain. But a growing number of studies are starting to show some encouraging results.

A 2025 study from the UK Medical Cannabis Registry found that cannabis-based medicines were associated with improvements in pain, sleep, and quality of life11 for patients with inflammatory arthritis, such as rheumatoid arthritis.

But the picture isn’t always clear-cut.

Back in 2025, the CANOA trial12 discovered that taking CBD-rich oil was unable to outperform a placebo when treating knee osteoarthritis, despite being well tolerated by patients.

This echoed the results of a 2024 scoping review,13 which described the current evidence for osteoarthritis as “mixed” and highlighted a need for further research.

Keeping clinical research in perspective

While much of the research into chronic pain and medical cannabis has been encouraging, it’s important to keep it in context.

Many of the studies have so far been observational and can’t be used to prove that the improvements were made by medical cannabis alone. This means higher-quality trials with larger sample sizes are still needed to confirm the relationship.

It’s also important to remember that medical cannabis is not currently recommended as a first-line treatment14 for chronic pain. That’s why any decision to prescribe it should always be made by a specialist, on a case-by-case basis.

What do existing Releaf patients think?

To better understand the real-world experiences of people who take medical cannabis, we surveyed 1,669 of our own Releaf patients back in November 2025, in what was the largest patient survey of its kind at the time.

Of these patients, almost half of the respondents (48%) named chronic pain as the main reason for their prescription, which led to some interesting findings:

  • 92.2% reported that their prescribed medical cannabis was effective in managing their symptoms

  • 96.2% of respondents said their quality of life had improved since starting treatment

  • 85.9% said their ability to work or study had improved

  • 88.8% reported experiencing no side effects, with those who did able to manage them through discussions with their clinical team

While these results are highly encouraging, it’s important to remember that they are self-reported and reflect our patients’ experiences at the time. In other words, they can only be used to show overall trends rather than guaranteed outcomes.

Who can be prescribed medical cannabis?

Every patient responds differently to medical cannabis, which is why you’ll need to be assessed by a medical professional to determine your eligibility for a prescription.

To legally access medical cannabis in the UK, it must be prescribed to you by a physician on the General Medical Council (GMC) Specialist Register.15

This means your regular GP will be unable to prescribe medical cannabis to you themselves. Most patients can only access it via a specialist at a private, CQC-regulated clinic.

Since medical cannabis is also not currently available on the NHS16 for chronic pain, you will need to book a consultation at a private clinic to see if you’re eligible.

To be considered, you’ll need to have:

  • A confirmed diagnosis of a qualifying condition from a medical professional.

  • Tried at least two conventional treatments that have been unable to provide adequate relief or resulted in unwanted side effects.

  • Not been previously diagnosed with psychosis, schizophrenia, or bipolar disorder.

You also won’t be able to access a medical cannabis prescription if you are currently pregnant or breastfeeding.

What side effects does medical cannabis cause?

Medical cannabis doesn’t work the same way for everyone and, as with any other type of prescription medication, there are certain risks and side effects involved.

The most commonly reported side effects16 can include:

  • Boca seca.

  • Dolores de cabeza.

  • Dizziness or lightheadedness.

  • Increased appetite.

  • Mood-related changes.

  • Red eyes.

  • Aumento de la frecuencia cardíaca.

  • Changes in blood pressure.

Cannabis can also interact with other medications,17 which is why it’s so important to give a full medical history to your prescribing clinician during your initial consultation.

That way, they can provide you with a tailored plan designed to minimise any potential risks and side effects.

Speaking to a medical cannabis specialist

If you’re living with chronic pain and conventional treatments haven’t given you the relief you’re looking for, our team at Releaf can help determine whether medical cannabis would be an appropriate alternative option.

Getting started with us only takes three simple steps:

1. Check your eligibility
Answer three quick questions about your medical history. It only takes around 2 minutes, with no GP referral needed and no obligation to book.

2. Meet your specialist
Book a video consultation with one of our GMC Specialist-registered clinicians, who’ll review your medical history and talk you through your options.

3. Start your treatment
If your specialist decides medical cannabis is right for you, they’ll agree a personalised treatment plan with you.

Initial consultations with Releaf currently cost £29.99 and, if your specialist decides medical cannabis isn’t a suitable option for you, you’ll receive a full refund. Terms apply.

This article is sponsored by Releaf.
Medical cannabis is only available on prescription following a consultation with a specialist doctor, and isn’t suitable for everyone. Always speak to a healthcare professional before starting any new treatment.

Lecturas adicionales y referencias

  1. Opioids: risk of dependence and addiction; GOV.UK
  2. Government announces that medicinal cannabis is legal; GOV.UK
  3. A. Fayaz et al.; Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ
  4. Back pain - low (without radiculopathy)/Prevalence; NICE CKS, August 2026 (UK access only)
  5. Dolor crónico (primario y secundario) en mayores de 16 años: evaluación de todo el dolor crónico y manejo del dolor crónico primario; Guía NICE (abril 2021)
  6. Dydyk AM, Jain NK, Gupta M; Opioid Use Disorder: Evaluation and Management.
  7. Capodice JL, Kaplan SA; The endocannabinoid system, cannabis, and cannabidiol: Implications in urology and men's health. Curr Urol. 2021 Jun;15(2):95-100. doi: 10.1097/CU9.0000000000000023. Epub 2021 May 28.
  8. Evans L, Erridge S, Varadpande M, et al; UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Complex Regional Pain Syndrome. Brain Behav. 2025 Sep;15(9):e70823. doi: 10.1002/brb3.70823.
  9. Leweke, F. et al; Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (2012)
  10. Karst, M et al; Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. Nat Med. 31: 4189–4196. (2025)
  11. Francis A, Erridge S, Holvey C, et al; Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry. Int Clin Psychopharmacol. 2025 Jul 1;40(4):242-249. doi: 10.1097/YIC.0000000000000556. Epub 2024 Jul 2.
  12. Mojoli A, Haider O, Fakih Y, et al; Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial – CANOA – cannabis for osteoarthritis. Front Pharmacol. 2025 Dec 19;16:1657065. doi: 10.3389/fphar.2025.1657065. eCollection 2025.
  13. A.T.Y. Xiao et al; Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review. Clin Rheumatol. 2024;43(8):2375-2390
  14. Productos medicinales a base de cannabis; Guía NICE (noviembre 2019 - última actualización marzo 2021)
  15. Información para médicos sobre productos a base de cannabis para uso medicinal (CBPMs); Consejo Médico General
  16. Medical cannabis (and cannabis oils); NHS (2022)
  17. Cannabis Interactions; Drugs.com

Historial del artículo

La información en esta página es revisada por pares por clínicos calificados.

Únete a la conversación

Comparte tus pensamientos o experiencias con otros en nuestro comunidades de pacientes.

Discusiones relacionadas

Ver más discusiones
Aviso legal: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.
verificador de elegibilidad para la gripe

Pregunta, comparte, conecta.

Navega por discusiones, haz preguntas y comparte experiencias en cientos de temas de salud.

verificador de síntomas

¿Te sientes mal?

Evalúa tus síntomas en línea de forma gratuita

Suscríbete al boletín de Patient

Tu dosis semanal de consejos de salud claros y confiables, escritos para ayudarte a sentirte informado, seguro y en control.

Por favor, introduce una dirección de correo electrónico válida

Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.